Estatísticas Básicas
| LEI | 52990017AIJPRH3HQH40 |
| CIK | 1636282 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Spyre Therapeutics, Inc.
SEC Filings (Chronological Order)
Esta página fornece uma lista completa e cronológica de Arquivamentos da SEC, excluindo os arquivamentos de propriedade que fornecemos em outro lugar.
| June 1, 2026 |
FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED LICENSE AGREEMENT This First Amendment to Amended and Restated License Agreement (this “First Amendment”) is dated as of May 29, 2026 (the “Amendment Effective Date”) and is entered into by and between Paragon Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (“Paragon”), having its principal place of business a |
|
| June 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2026 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 29, 2026 |
Exhibit 10.1 SPYRE THERAPEUTICS, INC. AMENDED AND RESTATED 2016 EMPLOYEE STOCK PURCHASE PLAN (as amended and restated effective January 1, 2026) 1. PURPOSE. Spyre Therapeutics, Inc. originally adopted this Plan effective as of the date of the initial public offering of the Common Stock and has subsequently amended and restated this Plan to be effective as of January 1, 2026 (the “Effective Date”). |
|
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2026 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 SPYRE THERAPEUTICS, INC. |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 5, 2026 |
Exhibit 99.1 Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class Announced over-enrollment and acceleration of topline readout to the third quarter of 2026 of the rh |
|
| April 16, 2026 |
Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-293600 PROSPECTUS SUPPLEMENT (To Prospectus dated February 27, 2026) 6,500,000 Shares Common Stock We are offering 6,500,000 shares of our common stock, par value $0.0001 per share (“common stock”). The public offering price for each share of common stock is $62.00. Our common stock is traded on the Nasdaq Global Select Market under t |
|
| April 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2026 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 16, 2026 |
Spyre Therapeutics, Inc. 6,500,000 Shares of Common Stock, Par Value $0.0001 UNDERWRITING AGREEMENT Exhibit 1.1 Spyre Therapeutics, Inc. 6,500,000 Shares of Common Stock, Par Value $0.0001 UNDERWRITING AGREEMENT April 14, 2026 JEFFERIES LLC GOLDMAN SACHS & CO. LLC EVERCORE GROUP L.L.C. GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o Ever |
|
| April 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2026 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 13, 2026 |
exhibit992set2 |
|
| April 13, 2026 |
SUBJECT TO COMPLETION, DATED APRIL 13, 2026 The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| April 13, 2026 |
Exhibit 99.1 Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical remission by modified Mayo Score of 40 |
|
| April 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2026 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 10, 2026 |
re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37722 SPYRE THERAPEUTICS, INC. |
|
| April 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| February 27, 2026 |
As filed with the Securities and Exchange Commission on February 27, 2026. As filed with the Securities and Exchange Commission on February 27, 2026. Registration No. 333-285341 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 (Post-Effective Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Spyre Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4312787 (State or other jurisdictio |
|
| February 25, 2026 |
SPYRE THERAPEUTICS, INC. 221 Crescent Street Building 23, Suite 105 Waltham, Massachusetts 02453 (617) 651-5940 February 25, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 RE: Spyre Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-293600) Request for Acceleration Ladies and Gentlemen: Pursuant to |
|
| February 25, 2026 |
February 25, 2026 Cameron Turtle Chief Executive Officer Spyre Therapeutics, Inc. 221 Crescent Street Building 23, Suite 105 Waltham, MA 02453 Re: Spyre Therapeutics, Inc. Registration Statement on Form S-3 Filed February 19, 2026 File No. 333-293600 Dear Cameron Turtle: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 4 |
|
| February 19, 2026 |
NOTICE OF RESTRICTED STOCK UNIT AWARD SPYRE THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN Exhibit 10.5 NOTICE OF RESTRICTED STOCK UNIT AWARD SPYRE THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN Unless otherwise defined herein, the terms defined in the Spyre Therapeutics, Inc. (the “Company”) 2016 Equity Incentive Plan (as amended from time to time, the “Plan”) shall have the same meanings in this Notice of Restricted Stock Unit Award (the “Notice”) and the attached Restricted Stock Unit |
|
| February 19, 2026 |
Exhibit 4.2 SPYRE THERAPEUTICS, INC. Debt Securities Indenture Dated as of , 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7.06 314 |
|
| February 19, 2026 |
Calculation of Filing Fee Tables FORM S-8 (Form Type) Spyre Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.0001 pe |
|
| February 19, 2026 |
As filed with the Securities and Exchange Commission on February 19, 2026. As filed with the Securities and Exchange Commission on February 19, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Spyre Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4312787 (State or other jurisdiction of incorporation or organization) (I. |
|
| February 19, 2026 |
Exhibit 99.1 Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with enrollment continuing ahead of schedule Enrollment on track in Ph |
|
| February 19, 2026 |
Subsidiaries of Spyre Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Spyre Therapeutics, Inc. None. |
|
| February 19, 2026 |
Calculation of Filing Fee Tables S-3 Spyre Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward In |
|
| February 19, 2026 |
re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K Table of Contents re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37722 SPYRE THERAPEUTICS, INC. |
|
| February 19, 2026 |
As filed with the Securities and Exchange Commission on February 19, 2026 As filed with the Securities and Exchange Commission on February 19, 2026 Registration No. |
|
| February 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 12, 2026 |
EX-99.2 Exhibit 99.2 CORPORATE OVERVIEW January 2026 Disclosures The information contained in this presentation has been prepared by Spyre Therapeutics, Inc. and its affiliates (“Spyre” or the “Company”) and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subject to change witho |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 12, 2026 |
EX-99.1 Exhibit 99.1 Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of- Concept Readouts Beginning in Q2 “6 in ’26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now expected to sta |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 SPYRE THERAPEUTICS, INC. |
|
| November 4, 2025 |
Exhibit 99.1 Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing Initiated Phase 2 SKYWAY basket study of SPY072 evaluating TL1A |
|
| November 4, 2025 |
Exhibit 99.2 Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7 + IL-23) and SPY230 (TL1A + IL-23) investigational combination thera |
|
| October 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2025 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| October 15, 2025 |
Spyre Therapeutics, Inc. 14,864,865 Shares of Common Stock, Par Value $0.0001 UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 Spyre Therapeutics, Inc. 14,864,865 Shares of Common Stock, Par Value $0.0001 UNDERWRITING AGREEMENT October 13, 2025 JEFFERIES LLC TD SECURITIES (USA) LLC LEERINK PARTNERS LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o TD Securities (USA) LLC 1 Vanderbilt Avenue, 11th |
|
| October 14, 2025 |
14,864,865 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| October 14, 2025 |
SUBJECT TO COMPLETION, DATED OCTOBER 13, 2025 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| October 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2025 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 5, 2025 |
orm of Warrant to Purchase Common Stock (Parapyre Warrant 2024) Exhibit 4.2 SPYRE THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK Number of Warrant Shares: 848,184 (subject to adjustment) Warrant No. SYRE-002 Original Issue Date: December 31, 2024 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, Parapyre Holding LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise |
|
| August 5, 2025 |
Exhibit 99.1 Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Reported positive interim Phase 1 results for two next-generation TL1A antibodies, demonstrating both were well-tolerated, exhibited pharmacokinetic ("PK") profiles supporting quarterly or biannual dosing, and full TL1A engagement through up to 20 weeks of follow-up Initiated Phase 2 SKYLINE |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 5, 2025 |
Form of Warrant to Purchase Common Stock (Parapyre Warrant 2023) Exhibit 4.1 SPYRE THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK Number of Warrant Shares: 684,407 (subject to adjustment) Warrant No. SYRE-001R Original Issue Date: December 29, 2023 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, Parapyre Holding LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise |
|
| August 5, 2025 |
As filed with the Securities and Exchange Commission on August 5, 2025 As filed with the Securities and Exchange Commission on August 5, 2025 Registration No. |
|
| August 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) Spyre Therapeutics, Inc. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 SPYRE THERAPEUTICS, INC. |
|
| August 5, 2025 |
EXHIBIT 10.1 AEGLEA BIOTHERAPEUTICS, INC. 2018 EQUITY INDUCEMENT PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract eligible persons whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company’s future performance thro |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 17, 2025 |
EX-99.2 Exhibit 99.2 Anti-TL1A Phase 1 Results and Phase 2 Development Updates June 2025 Disclosures The information contained in this presentation has been prepared by Spyre Therapeutics, Inc. and its affiliates (“Spyre” or the “Company”) and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the dat |
|
| June 17, 2025 |
Exhibit 99.1 Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next- Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated, mo |
|
| June 2, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| June 2, 2025 |
June 2, 2025 Scott Burrows Chief Financial Officer Spyre Therapeutics, Inc. 221 Crescent Street Building 23 Suite 105 Waltham, MA 02453 Re: Spyre Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed February 27, 2025 File No. 001-37722 Dear Scott Burrows: We have completed our review of your filing. We remind you that the company and its management are responsible for the |
|
| May 21, 2025 |
Securities and Exchange Commission May 21, 2025 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| May 9, 2025 |
May 9, 2025 Scott Burrows Chief Financial Officer Spyre Therapeutics, Inc. 221 Crescent Street Building 23 Suite 105 Waltham, MA 02453 Re: Spyre Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed February 27, 2025 File No. 001-37722 Dear Scott Burrows: We have limited our review of your filing to the financial statements and related disclosures and have the following co |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 SPYRE THERAPEUTICS, INC. |
|
| May 8, 2025 |
Exhibit 99.1 Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts in 2026 & 2027 Reported extended follow-up Phase 1 data for SPY001, supporting that the molecule is well tolerated, has a pharm |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 7, 2025 |
As filed with the Securities and Exchange Commission on March 7, 2025. As filed with the Securities and Exchange Commission on March 7, 2025. Registration No. 333-281975 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 (Post-Effective Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Spyre Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4312787 (State or other jurisdiction of |
|
| March 6, 2025 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 6, 2025 |
Letter from PricewaterhouseCoopers LLP, dated March 6, 2025 Exhibit 16.1 March 6, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Spyre Therapeutics, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Spyre Therapeutics, Inc. dated March 6, 2025. We agree with the statements concerning our |
|
| March 5, 2025 |
March 5, 2025 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 4, 2025 |
March 4, 2025 Heidy King-Jones Chief Legal Officer and Corporate Secretary Spyre Therapeutics, Inc. |
|
| February 27, 2025 |
Exhibit 10.25 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Version AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (“Agreement”) is executed as of February 24, 2025 (the “Res |
|
| February 27, 2025 |
re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K Table of Contents re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37722 SPYRE THERAPEUTICS, INC. |
|
| February 27, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Spyre Therapeutics, Inc. Name of Subsidiary Jurisdiction Aeglea Biotherapeutics UK Limited England and Wales Aeglea Ireland Limited Ireland |
|
| February 27, 2025 |
Exhibit 1.2 SPYRE THERAPEUTICS, INC. $200,000,000 COMMON STOCK SALES AGREEMENT September 6, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agree |
|
| February 27, 2025 |
Description of the Registrant's securities Exhibit 4.4 DESCRIPTION OF CAPITAL STOCK General The following description summarizes the material terms of the capital stock of Spyre Therapeutics, Inc. (“we,” “us,” “our” or the “company”), as well as other material terms of our second amended and restated certificate of incorporation (“Certificate of Incorporation”) and amended and restated bylaws (“Bylaws”) and certain provisions of Delaware l |
|
| February 27, 2025 |
Form of Warrant to Purchase Common Stock (Parapyre Warrant 202 Exhibit 4.6 SPYRE THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK Number of Warrant Shares: 848,184 (subject to adjustment) Original Issue Date: December 31, 2024 Warrant No. SYRE-002 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, Parapyre Holding LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 27, 2025 |
Spyre Therapeutics, Inc. Insider Trading Policy Exhibit 19.1 SPYRE THERAPEUTICS, INC. INSIDER TRADING POLICY (dated February 1, 2024) I. INTRODUCTION Federal and state laws prohibit buying, selling or making other transfers of securities by persons who have material information that is not generally known or available to the public. These laws also prohibit persons with such material nonpublic information (“MNPI”) from disclosing this informati |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Exhibit 99.1 Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million public offering Continued execution towards expected milestones across portfolio, with interim Phase 1 data readou |
|
| February 27, 2025 |
Calculation of Filing Fee Tables S-3 Spyre Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective |
|
| February 27, 2025 |
Exhibit 4.2 SPYRE THERAPEUTICS, INC. Debt Securities Indenture Dated as of , 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7.06 314 |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025. As filed with the Securities and Exchange Commission on February 27, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Spyre Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4312787 (State or other jurisdiction of incorporation or organization) (I. |
|
| February 27, 2025 |
Calculation of Filing Fee Tables FORM S-8 (Form Type) Spyre Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.0001 pe |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025110249.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Spyre Therapeutics, Inc. and further agree that this |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 13, 2025 |
Exhibit 99.1 Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025 Phase 1 interim results expected for SPY003, an extended half-life IL-23 antibody, in 2H2025 Phase 2 platform trial in ulcerative colitis (UC) remains on track for initiation in mid-2025 |
|
| January 13, 2025 |
Exhibit 99.2 Corporate overview January 2025 Disclosures The information contained in this presentation has been prepared by Spyre Therapeutics, Inc. and its affiliates (“Spyre” or the “Company”) and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notic |
|
| November 19, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-281975 PROSPECTUS SUPPLEMENT (To Prospectus dated September 18, 2024) 7,275,000 Shares Common Stock We are offering 7,275,000 shares of our common stock, par value $0.0001 per share (“common stock”). The public offering price for each share of common stock is $27.50. Our common stock is traded on the Nasdaq Global Select Market under |
|
| November 19, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 19, 2024 |
Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC Exhibit 1.1 Spyre Therapeutics, Inc. 7,275,000 Shares of Common Stock, Par Value $0.0001 UNDERWRITING AGREEMENT November 18, 2024 JEFFERIES LLC GOLDMAN SACHS & CO. LLC EVERCORE GROUP L.L.C. GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o GOLDMAN SACHS & CO. LLC 200 West Street New York, New York 10282 c/o E |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| November 18, 2024 |
SUBJECT TO COMPLETION, DATED NOVEMBER 18, 2024 Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-281975 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not per |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| November 18, 2024 |
Table of Contents re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A (Amendment No. |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 14, 2024 |
SYRE / Spyre Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d912069dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Spyre Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00773J202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement |
|
| November 14, 2024 |
AGLE / Aeglea BioTherapeutics Inc / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-syre093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Spyre Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 00773J103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Ch |
|
| November 14, 2024 |
SC 13G/A 1 p24-3032sc13ga.htm SPYRE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Spyre Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00773J202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check t |
|
| November 14, 2024 |
SC 13G/A 1 tm2428137d15sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Spyre Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 00773J202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this State |
|
| November 14, 2024 |
SYRE / Spyre Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Spyre Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00773J202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| November 12, 2024 |
SYRE / Spyre Therapeutics, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 SPYRE THERAPEUTICS INC COMMON STOCK Cusip #00773J202 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00773J202 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,623,881 Item 6: 0 Item 7: 7,623,881 Item 8: 0 Item |
|
| November 12, 2024 |
SPY001 Phase 1 Results & Corporate Updates November 2024 2 Disclosures The information contained in this presentation has been prepared by Spyre Therapeutics, Inc. |
|
| November 12, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 12, 2024 |
Exhibit 99.1 Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing SPY001 was well tolerated with a favorable safety profile consistent with the anti-α4β7 class S |
|
| November 8, 2024 |
SYRE / Spyre Therapeutics, Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us00773j2024110824.txt us00773j2024110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) SPYRE THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 00773J202 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| November 7, 2024 |
Exhibit 99.1 Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fourth quarter of 2024 Presented new data on SPY003, a potential best-in-class half-life extende |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 7, 2024 |
Fifth Amendment to the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan Exhibit 10.4 FIFTH AMENDMENT TO THE SPYRE THERAPEUTICS, INC. 2018 EQUITY INDUCEMENT PLAN WHEREAS, Spyre Therapeutics, Inc., a Delaware corporation (the “Company”) maintains the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended on June 22, 2023, August 30, 2023, October 30, 2023 and November 28, 2023 (the “Plan”); and WHEREAS, pursuant to Section 17 of the Plan, the Board of Director |
|
| November 7, 2024 |
EXHIBIT 99.1 AEGLEA BIOTHERAPEUTICS, INC. 2018 EQUITY INDUCEMENT PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract eligible persons whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company’s future performance thro |
|
| November 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) Spyre Therapeutics, Inc. |
|
| November 7, 2024 |
, 2024, by and between the Company and Sheldon Sloan Exhibit 10.5 September 20, 2024 Dr. Sheldon Sloan, M.D. Re: Offer of Employment Dear Sheldon: On behalf of Spyre Therapeutics, Inc. (the “Company”), I am very pleased to offer you a position as Chief Medical Officer (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below. Your employment with the Company in the Role will |
|
| November 7, 2024 |
As filed with the Securities and Exchange Commission on November 7, 2024 As filed with the Securities and Exchange Commission on November 7, 2024 Registration No. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 SPYRE THERAPEUTICS, INC. |
|
| October 23, 2024 |
SYRE / Spyre Therapeutics, Inc. / Deutsch Peter E. - SCHEDULE 13G Passive Investment SC 13G 1 deutsch13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Spyre Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.0001 (Title of Class of Securities) 00773J202 (CUSIP Number) October 14, 2024 (Date of Event which Requires Filing of this Statement) Check the appro |
|
| October 22, 2024 |
SYRE / Spyre Therapeutics, Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us00773j2024102224.txt us00773j2024102224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) SPYRE THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 00773J202 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| October 15, 2024 |
Exhibit 10.2 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED BIOLOGICS MASTER SERVICES AGREEMENT This Amended and Restated Biologics Master Services Agreement (this “Agreement”) is effective as of the latest d |
|
| October 15, 2024 |
Exhibit 99.1 Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre’s Portfolio of Potentially Best-in-Class Antibodies and Combinations SPY003, a novel half-life extended IL-23p19 monoclonal antibody (mAb), with first-in-human dosing now expected first quarter 2025 New data on SPY003 presented at UEGW demonstrating rob |
|
| October 15, 2024 |
Exhibit 10.3 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED CELL LINE LICENSE AGREEMENT This Amended and Restated Cell Line License Agreement (“Agreement”), effective as of the latest date of signatur |
|
| October 15, 2024 |
Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTION VERSION LICENSE AGREEMENT THIS LICENSE AGREEMENT (“Agreement”) is entered into and effective as of October 11, 2024 (the “Effective Date”), by and betw |
|
| October 15, 2024 |
Exhibit 99.2 Corporate overview October 2024 Disclosures The information contained in this presentation has been prepared by Spyre Therapeutics, Inc. and its affiliates (“Spyre” or the “Company”) and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notic |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 30, 2024 |
September 30, 2024 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 26, 2024 |
September 26, 2024 Cameron Turtle Chief Executive Officer Spyre Therapeutics, Inc. |
|
| September 20, 2024 |
As filed with the Securities and Exchange Commission on September 20, 2024. As filed with the Securities and Exchange Commission on September 20, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Spyre Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4312787 (State or other jurisdiction of incorporation or organization) (I |
|
| September 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Spyre Therapeutics, Inc. |
|
| September 13, 2024 |
September 13, 2024 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 12, 2024 |
September 12, 2024 Heidy King-Jones Chief Legal Officer Spyre Therapeutics, Inc. 221 Crescent Street Building 23, Suite 105 Waltham, MA 02453 Re: Spyre Therapeutics, Inc. Registration Statement on Form S-3 Filed September 6, 2024 File No. 333-281975 Dear Heidy King-Jones: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and |
|
| September 6, 2024 |
Exhibit 1.2 SPYRE THERAPEUTICS, INC. $200,000,000 COMMON STOCK SALES AGREEMENT September 6, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agree |
|
| September 6, 2024 |
As filed with the Securities and Exchange Commission on September 6, 2024. As filed with the Securities and Exchange Commission on September 6, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Spyre Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4312787 (State or other jurisdiction of incorporation or organization) (I. |
|
| September 6, 2024 |
Exhibit 4.2 SPYRE THERAPEUTICS, INC. Debt Securities Indenture Dated as of , 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7.06 314 |
|
| September 6, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Spyre Therapeutics, Inc. |
|
| August 8, 2024 |
SPYRE THERAPEUTICS, INC. 33,361,402 Shares Common Stock Offered by the Selling Stockholders Table of Contents Prospectus Supplement No. 2 Filed Pursuant to Rule 424(b)(3) (to prospectus dated April 29, 2024) Registration No. 333-278810 SPYRE THERAPEUTICS, INC. 33,361,402 Shares Common Stock Offered by the Selling Stockholders This prospectus supplement no. 2 is being filed to update and supplement information contained in the prospectus dated April 18, 2024 (the “Prospectus”), which form |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorp |
|
| August 7, 2024 |
Exhibit 10.3 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT This License Agreement (“Agreement”) is entered into and effective as of May 14, 2024 (the “Effective Date”), by and between Paragon Therapeutics, Inc., a c |
|
| August 7, 2024 |
Exhibit 10.5 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SECOND AMENDED AND RESTATED ANTIBODY DISCOVERY AND OPTION AGREEMENT This Second Amended and Restated Antibody Discovery and Option Agreement (“Agreement”) is entered into and |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 SPYRE THERAPEUTICS, INC. |
|
| August 7, 2024 |
Exhibit 10.4 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT This License Agreement (“Agreement”) is entered into and effective as of May 14, 2024 (the “Effective Date”), by and between Paragon Therapeutics, Inc., a c |
|
| August 7, 2024 |
Exhibit 10.7 NOTICE OF RESTRICTED STOCK UNIT AWARD SPYRE THERAPEUTICS, INC. 2018 EQUITY INDUCEMENT PLAN Unless otherwise defined herein, the terms defined in the Spyre Therapeutics, Inc. (the “Company”) 2018 Equity Inducement Plan (the “Plan”) shall have the same meanings in this Notice of Restricted Stock Unit Award (the “Notice”) and the attached Restricted Stock Unit Agreement (the “RSU Agreeme |
|
| August 7, 2024 |
Exhibit 10.6 NOTICE OF STOCK OPTION GRANT SPYRE THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN Unless otherwise defined herein, the terms defined in the Spyre Therapeutics, Inc. (the “Company”) 2016 Equity Incentive Plan (as amended and restated, the “Plan”) shall have the same meanings in this Notice of Stock Option Grant (the “Notice of Grant”) and the attached Stock Option Agreement (the “Option |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):May 9, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 7, 2024 |
Exhibit 99.1 Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update Initiated dosing in Phase 1 trial of SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous maintenance dosing, with interim proof-of-concept data on track for year-end 2024 SPY002, an anti-TL1A antibody program designed for enhanced potency to both TL1A monomers and trimers, |
|
| June 10, 2024 |
SYRE / Spyre Therapeutics, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No.3 SPYRE THERAPEUTICS INC COMMON STOCK Cusip #00773J202 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00773J202 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 6,583,155 Item 6: 0 Item 7: 6,583,155 Item 8: 0 Item 9: 6,583,155 Item 11: |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 30, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 15, 2024 |
SPYRE THERAPEUTICS, INC. 33,361,402 Shares Common Stock Offered by the Selling Stockholders Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-278810 Prospectus Supplement No. 1 (to prospectus dated April 29, 2024) SPYRE THERAPEUTICS, INC. 33,361,402 Shares Common Stock Offered by the Selling Stockholders This prospectus supplement no. 1 is being filed to update and supplement information contained in the prospectus dated April 18, 2024 (the “Prospectus”), which form |
|
| May 15, 2024 |
Exhibit 99.1 Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors WALTHAM, Mass., May 15, 2024 (PR NEWSWIRE)—Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatme |
|
| May 15, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SPYRE THERAPEUTICS, INC. Spyre Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify: 1. The current name of the Corporation is Spyre |
|
| May 15, 2024 |
Exhibit 3.2 SPYRE THERAPEUTICS, INC. SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Spyre Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1. The current name of the Corporation is Spyre Therapeutics, In |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 13, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 9, 2024 |
Exhibit 10.6 AMENDMENT NO. 1 TO THE NOVATION AGREEMENT This Amendment No. 1 (the “Amendment”), effective as of April 25, 2024 (the “Amendment Effective Date”) to the Novation Agreement effective as of July 21, 2023 and executed on September 19, 2023 (the “Novation Agreement”) is entered into by and among (i) Paragon Therapeutics, Inc., a Delaware corporation with an office at 221 Crescent Street, |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37722 SPYRE THERAPEUTICS, INC. |
|
| May 9, 2024 |
Exhibit 99.1 Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous dosing successfully completed a 28-day GLP toxicity study and remains on track to begin first-in-human studies in the second quarter of 2024, with interim proof-of-concept data expected year-end 2024 SPY002, an anti-TL1A an |
|
| May 9, 2024 |
Form of Warrant to Purchase Common Stock (Parapyre Warrant 2023) E Exhibit 4.2 SPYRE THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK Number of Warrant Shares: 684,407 (subject to adjustment) Original Issue Date: December 29, 2023 Warrant No. SYRE-001R THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, Parapyre Holding LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exerci |
|
| April 25, 2024 |
April 25, 2024 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 25, 2024 |
United States securities and exchange commission logo April 25, 2024 Heidy King-Jones Chief Legal Officer Spyre Therapeutics, Inc. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 23, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 25, 2024 |
SYRE / Spyre Therapeutics, Inc. / Fairmount Funds Management LLC - SC 13D/A Activist Investment SC 13D/A 1 d820181dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) SPYRE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00773J 202 (CUSIP Number) Ms. Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive, Suite 400 Wes |
|
| April 25, 2024 |
Exhibit 10.1 April 23, 2024 Spyre Therapeutics, Inc. 221 Crescent St., Building 23, Unit 105 Waltham, MA 02453 Attention: Scott Burrows Re: 3(a)(9) Exchange Agreement Ladies and Gentlemen: This letter agreement (the “Agreement”) confirms the agreement of Spyre Therapeutics, Inc. (the “Company”), and the holder of the Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share, of |
|
| April 23, 2024 |
SC 13G/A 1 p24-1535sc13ga.htm SPYRE THERAPEUTICS INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Spyre Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00773J202 (CUSIP Number) December 31, 2023** (Date of Event Which Requires Filing of This Statement) Check the |
|
| April 19, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on April 18, 2024 Registration No. |
|
| April 19, 2024 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-1 (Form Type) Spyre Therapeutics, Inc. |
|
| April 2, 2024 |
April 2, 2024 Spyre Therapeutics, Inc. 221 Crescent Street Building 23, Suite 105 Waltham, MA 02456 Re: Spyre Therapeutics, Inc. Form S-1, as amended Exhibit Nos. 10.1, 10.2, and 10.5 Filed March 27, 2024 File No. 333-276251 Dear Cameron Turtle: We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response an |
|
| April 2, 2024 | ||
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 28, 2024 |
March 28, 2024 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 27, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on March 26, 2024 Registration No. |
|
| March 27, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on March 26, 2024 Registration No. |
|
| March 26, 2024 |
Gibson, Dunn & Crutcher LLP One Embarcadero Center, Suite 2600 San Francisco, CA 94111-3715 Tel 415. |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 18, 2024 |
Form of Registration Rights Agreement (March 2024 PIPE) EX-10.2 Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of March 18, 2024, by and among Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made purs |
|
| March 18, 2024 |
Spyre Therapeutics Announces $180 Million Private Placement EX-99.1 Exhibit 99.1 Spyre Therapeutics Announces $180 Million Private Placement WALTHAM, Mass., March 18, 2024 (PR NEWSWIRE)—Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ: SYRE), a biotechnology company advancing a pipeline of investigational antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (“IBD”), today announced that it has entered |
|
| March 18, 2024 |
SPYRE THERAPEUTICS, INC. 18,809,064 Shares Common Stock Offered by the Selling Stockholders Prospectus Supplement No. 4 Filed Pursuant to Rule 424(b)(3) (to prospectus dated November 20, 2023) Registration No. 333-273769 SPYRE THERAPEUTICS, INC. 18,809,064 Shares Common Stock Offered by the Selling Stockholders This prospectus supplement no. 4 is being filed to update and supplement information contained in the prospectus dated November 20, 2023 (the “Prospectus”) related to the proposed |
|
| March 18, 2024 |
EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 18, 2024, by and among SPYRE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 18, 2024 |
EX-3.2 Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK OF SPYRE THERAPEUTICS, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware Spyre Therapeutics, Inc., a Delaware corporation (the “Corporation”), hereby certifies as follows: FIRST: The Corporation’s |
|
| March 14, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on March 14 , 2024 Registration No. |
|
| March 14, 2024 |
Gibson, Dunn & Crutcher LLP One Embarcadero Center, Suite 2600 San Francisco, CA 94111-3715 Tel 415. |
|
| March 14, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on March 14, 2024 Registration No. |
|
| March 11, 2024 |
SYRE / Spyre Therapeutics, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No.2 SPYRE THERAPEUTICS INC COMMON STOCK Cusip #00773J202 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00773J202 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 6,584,175 Item 6: 0 Item 7: 6,584,175 Item 8: 0 Item 9: 6,584,175 Item 11: |
|
| March 8, 2024 |
United States securities and exchange commission logo March 8, 2024 Cameron Turtle Chief Executive Officer Spyre Therapeutics, Inc. |
|
| March 5, 2024 |
As filed with the Securities and Exchange Commission on March 5, 2024 Registration No. |
|
| March 1, 2024 |
Exhibit 10.19 August 18, 2023 Heidy King-Jones Re: Offer of Employment Dear Heidy: On behalf of Aeglea BioTherapeutics, Inc. (the “Company”), I am very pleased to offer you a position as Chief Legal Officer and Corporate Secretary (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below. Your employment with the Company i |
|
| March 1, 2024 |
Exhibit 10.8 SPYRE THERAPEUTICS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN (as amended by the First Amendment on January 31, 2024) 1. PURPOSE. Spyre Therapeutics, Inc. has adopted this Plan effective as of the date of the IPO. The purpose of this Plan is to provide eligible employees of the Company and the Participating Corporations with a means of acquiring an equity interest in the Company and to e |
|
| March 1, 2024 |
Gibson, Dunn & Crutcher LLP One Embarcadero Center, Suite 2600 San Francisco, CA 94111-3715 Tel 415. |
|
| March 1, 2024 |
As filed with the Securities and Exchange Commission on March 1, 2024 Registration No. |
|
| March 1, 2024 |
Exhibit 10.20 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (together with the attached Exhibit A (the “Business Terms Exhibit”) and Exhibit B (the “EU Data Privacy Exhibit”), the “Agreement”), is made as of August 1, 2023 (the “Effective Date”) by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and Mark McKenna (“Consultant”). The Company desires to have the ben |
|
| March 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) Spyre Therapeutics, Inc. |
|
| March 1, 2024 |
re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A (Amendment No. |
|
| February 29, 2024 |
Spyre Therapeutics, Inc. Compensation Recoupment (Clawback) Policy Exhibit 97 SPYRE THERAPEUTICS, INC. COMPENSATION RECOUPMENT (CLAWBACK) POLICY (Adopted By Board on October 25, 2023) Recoupment of Incentive-Based Compensation It is the policy of Spyre Therapeutics, Inc. (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to the Company’s material non-compliance with any financi |
|
| February 29, 2024 |
Exhibit 10.4 SPYRE THERAPEUTICS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN (as amended by the First Amendment on January 31, 2024) 1. PURPOSE. Spyre Therapeutics, Inc. has adopted this Plan effective as of the date of the IPO. The purpose of this Plan is to provide eligible employees of the Company and the Participating Corporations with a means of acquiring an equity interest in the Company and to e |
|
| February 29, 2024 |
Consulting Agreement by and between the Company and Mark McKenna, effective August 1, 2023 Exhibit 10.20 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (together with the attached Exhibit A (the “Business Terms Exhibit”) and Exhibit B (the “EU Data Privacy Exhibit”), the “Agreement”), is made as of August 1, 2023 (the “Effective Date”) by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and Mark McKenna (“Consultant”). The Company desires to have the ben |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 29, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Spyre Therapeutics, Inc. Name of Subsidiary Jurisdiction Spyre Therapeutics LLC Delaware Aeglea Development Company, Inc. Delaware AERase, Inc. Delaware AECase, Inc. Delaware AEMase, Inc. Delaware AE4ase, Inc. Delaware AE5ase, Inc. Delaware AE6ase, Inc. Delaware Aeglea Biotherapeutics UK Limited England and Wales Aeglea Ireland Limited Ireland Aeglea BioTherapeutics US |
|
| February 29, 2024 |
Exhibit 99.1 Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Announced corporate name change to Spyre Therapeutics; appointment of Cameron Turtle, DPhil, as Chief Executive Officer; and began trading on Nasdaq under the symbol "SYRE" SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous dosing, demonstrated an updated hal |
|
| February 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) Spyre Therapeutics, Inc. |
|
| February 29, 2024 |
re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K Table of Contents re UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37722 SPYRE THERAPEUTICS, INC. |
|
| February 29, 2024 |
Description of the Registrant's securities Exhibit 4.5 DESCRIPTION OF CAPITAL STOCK General The following description summarizes the material terms of the capital stock of Spyre Therapeutics, Inc. (“we,” “us,” “our” or the “company”), as well as other material terms of our amended and restated certificate of incorporation (“Certificate of Incorporation”) and amended and restated bylaws (“Bylaws”) and certain provisions of Delaware law. Thi |
|
| February 29, 2024 |
Offer Letter, dated August 18, 2023, by and between the Company and Heidy King-Jones Exhibit 10.19 August 18, 2023 Heidy King-Jones Re: Offer of Employment Dear Heidy: On behalf of Aeglea BioTherapeutics, Inc. (the “Company”), I am very pleased to offer you a position as Chief Legal Officer and Corporate Secretary (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below. Your employment with the Company i |
|
| February 16, 2024 |
United States securities and exchange commission logo February 16, 2024 Cameron Turtle Chief Executive Officer Spyre Therapeutics, Inc. |
|
| February 14, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Spyre Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00773J 202 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Spyre Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00773J202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Spyre Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00773J 202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 14, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Spyre Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00773J202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 14, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 agle13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Spyre Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00773J202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| February 14, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / Rock Springs Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / Logos Global Management LP Passive Investment SC 13G/A 1 agle13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Spyre Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00773J202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 14, 2024 |
EX-99.1 2 d753218dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 14, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm242424d8sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Spyre Therapeutics, Inc. (f/k/a Aeglea Biotherapeutics, Inc.) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00773J202** (CUSIP Number) December 31, 2023 (Date of Event which Requires Fi |
|
| February 14, 2024 |
SC 13G/A 1 tm246235d20sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Spyre Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 00773J202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stateme |
|
| February 14, 2024 |
AGLE / Aeglea BioTherapeutics Inc / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-syre123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Spyre Therapeutics Inc. (Name of Issuer) Common Stock, $0.0001 Par Value Per Share (Title of Class of Securities) 00773J103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che |
|
| February 14, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / RTW INVESTMENTS, LP - SPYRE THERAPEUTICS, INC. Passive Investment SC 13G 1 p24-0715sc13g.htm SPYRE THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Spyre Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00773J202 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Che |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00773J202 (CUSIP Number) Michael Hirschberg, Esq. Reitler Kailas & Rosenblatt LLP 885 Third Avenue, |
|
| February 13, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / Polar Capital Holdings Plc Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / BCLS II Equity Opportunities, LP - SC 13G/A Passive Investment SC 13G/A 1 d784098dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 3) SPYRE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 |
|
| February 13, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 SPYRE THERAPEUTICS INC COMMON STOCK Cusip #00773J202 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00773J202 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 6,206,451 Item 6: 0 Item 7: 6,206,451 Item 8: 0 Item |
|
| February 9, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / FMR LLC Passive Investment SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 SPYRE THERAPEUTICS INC COMMON STOCK Cusip #00773J202 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00773J202 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 3,785,877 Item 6: 0 Item 7: 3,785,877 Item 8: 0 Item 9 |
|
| February 8, 2024 |
US00773J2024 / AEGLEA BIOTHERAP / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G/A 1 SYRESC13GA2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) SPYRE THERAPEUTICS, INC. (formerly Aeglea BioTherapeutics, Inc.) (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 00773J202 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires |
|
| February 7, 2024 |
SPYRE THERAPEUTICS, INC. 18,809,064 Shares Common Stock Offered by the Selling Stockholders Prospectus Supplement No. 3 Filed Pursuant to Rule 424(b)(3) (to prospectus dated November 20, 2023) Registration No. 333-273769 SPYRE THERAPEUTICS, INC. 18,809,064 Shares Common Stock Offered by the Selling Stockholders This prospectus supplement no. 3 is being filed to update and supplement information contained in the prospectus dated November 20, 2023 (the “Prospectus”) related to the proposed |
|
| February 5, 2024 |
Exhibit 10.2 February 1, 2024 Cameron Turtle Re: Amendment to Amended and Restated Employment Letter Agreement Dear Cameron: This letter, effective as of the date first set forth above (this “Amendment”), amends that certain amended and restated employment letter agreement between you and Spyre Therapeutics, Inc. (f/k/a Aeglea BioTherapeutics, Inc.) (the “Company”) dated November 22, 2023 (the “Ag |
|
| February 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) Spyre Therapeutics, Inc. |
|
| February 5, 2024 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SPYRE THERAPEUTICS, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of Spyre Therapeutics, Inc., a Delaware corporation (the “Corporation”), shall be fixed in the Certificate of Incorporation of the Corporation (as the same may be amended and/or restated from time to time, the “Certificate of |
|
| February 5, 2024 |
Exhibit 10.4 November 22, 2023 Cameron Turtle Re: Amended and Restated Employment Letter Agreement Dear Cameron: On behalf of Aeglea BioTherapeutics, Inc. (the “Company”), I am very pleased to offer you a position as Chief Executive Officer of the Company (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below, to be eff |
|
| February 5, 2024 |
Exhibit 10.19 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is entered into as of by and between Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), and (the “Indemnitee”) and shall be deemed effective upon the earliest date that the Indemnitee is duly elected or appointed as a director or officer of the Company. RECITALS WHEREAS, the Board of Directors |
|
| February 5, 2024 |
As filed with the Securities and Exchange Commission on February 2, 2024 Registration No. |
|
| February 5, 2024 |
Code of Business Conduct and Ethics of the Company, effective as of February 1, 2024. Exhibit 14.1 SPYRE THERAPEUTICS, INC. CODE OF BUSINESS CONDUCT AND ETHICS (dated February 1, 2024) I. INTRODUCTION This Code of Business Conduct and Ethics (this “Code”) provides a general statement of the expectations of Spyre Therapeutics, Inc. (the “Company”) regarding the ethical standards to which each director, officer and employee should adhere while acting on behalf of the Company. You are |
|
| February 5, 2024 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SPYRE THERAPEUTICS, INC. (a Delaware corporation) ARTICLE I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of Spyre Therapeutics, Inc., a Delaware corporation (the “Corporation”), shall be fixed in the Certificate of Incorporation of the Corporation (as the same may be amended and/or restated from time to time, the “Certificate of |
|
| February 5, 2024 |
Form of Indemnification Agreement. Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is entered into as of by and between Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), and (the “Indemnitee”) and shall be deemed effective upon the earliest date that the Indemnitee is duly elected or appointed as a director or officer of the Company. RECITALS WHEREAS, the Board of |
|
| February 5, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 1, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 2, 2024 |
Gibson, Dunn & Crutcher LLP One Embarcadero Center, Suite 2600 San Francisco, CA 94111-3715 Tel 415. |
|
| January 19, 2024 |
January 19, 2024 Spyre Therapeutics, Inc. 221 Crescent Street Building 23, Suite 105 Waltham, MA 02456 Re: Spyre Therapeutics, Inc. Registration Statement on Form S-1 Exhibit Nos. 10.1, 10.2, and 10.5 Filed December 22, 2023 File No. 333-276251 Dear Cameron Turtle: You have redacted information from the exhibits identified above asserting that the redacted information is not material and is the ty |
|
| January 18, 2024 |
United States securities and exchange commission logo January 18, 2024 Cameron Turtle Chief Executive Officer Spyre Therapeutics, Inc. |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 16, 2024 SPYRE THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37722 46-4312787 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 29, 2023 |
US00773J2024 / AEGLEA BIOTHERAP / Fairmount Funds Management LLC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) SPYRE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00773J 202 (CUSIP Number) Ms. Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive, Suite 400 West Conshohocken, PA 19428 (267) |
|
| December 22, 2023 |
Exhibit 10.14 SEVERANCE AGREEMENT This Severance Agreement (the “Agreement”) is entered into as of April , 2018 (the “Effective Date”) by and between (the “Executive”) and Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”). 1. Term of Agreement. This Agreement shall terminate on the date the Executive’s employment with the Company or its subsidiary, as applicable, terminates for |
|
| December 22, 2023 |
EXHIBIT 10.10 AEGLEA BIOTHERAPEUTICS, INC. 2018 EQUITY INDUCEMENT PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract eligible persons whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company’s future performance thr |
|
| December 22, 2023 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AEGLEA BIOTHERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Aeglea BioTherapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1. The current name of the Corporation is Aeglea BioTherapeutic |
|
| December 22, 2023 |
2016 Employee Stock Purchase Plan and forms of award agreements, as amended Exhibit 10.9 AEGLEA BIOTHERAPEUTICS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN 1. PURPOSE. Aeglea BioTherapeutics, Inc. has adopted this Plan effective as of the date of the IPO. The purpose of this Plan is to provide eligible employees of the Company and the Participating Corporations with a means of acquiring an equity interest in the Company and to enhance such employees’ sense of participation in |
|
| December 22, 2023 |
Power of Attorney (included on the signature page to the registration statement) As filed with the Securities and Exchange Commission on December 22, 2023 Registration No. |
|
| December 22, 2023 |
Offer Letter, dated August 10, 2023, by and between the Company and Scott Burrows Exhibit 10.16 August 10, 2023 Scott Burrows Re: Offer of Employment Dear Scott: On behalf of Aeglea BioTherapeutics, Inc. (the “Company”), I am very pleased to offer you a position as Chief Financial Officer (the “Role”) pursuant to this letter agreement (the “Agreement”), provided you accept such offer as indicated by your signature below. Your employment with the Company in the Role will commenc |
|
| December 22, 2023 |
Form of Stock Option Agreement under the Amended and Restated 2018 Equity Inducement Plan Exhibit 10.11 NOTICE OF STOCK OPTION GRANT AEGLEA BIOTHERAPEUTICS, INC. 2018 EQUITY INDUCEMENT PLAN Unless otherwise defined herein, the terms defined in the Aeglea BioTherapeutics, Inc. (the “Company”) 2018 Equity Inducement Plan (the “Plan”) shall have the same meanings in this Notice of Stock Option Grant (the “Notice of Grant”) and the attached Stock Option Agreement (the “Option Agreement”). |
|
| December 22, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) Spyre Therapeutics, Inc. |
|
| December 22, 2023 |
Exhibit 21.1 Subsidiaries of Aeglea BioTherapeutics, Inc. Name of Subsidiary Jurisdiction Aeglea Development Company, Inc. Delaware AERase, Inc. Delaware AECase, Inc. Delaware AEMase, Inc. Delaware AE4ase, Inc. Delaware AE5ase, Inc. Delaware AE6ase, Inc. Delaware Aeglea Biotherapeutics UK Limited England and Wales Aeglea Ireland Limited Ireland Aeglea BioTherapeutics US LLC Delaware Spyre Therapeu |
|
| December 22, 2023 |
Certificate of Designation of Series B Non-Voting Convertible Preferred Stock Exhibit 3.4 SPYRE THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Spyre Therapeutics, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted |
|
| December 22, 2023 |
EXHIBIT 99.1 SPYRE THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN AS AMENDED AND RESTATED EFFECTIVE NOVEMBER 21, 2023 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offe |
|
| December 22, 2023 |
Exhibit 10.2 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CELL LINE LICENSE AGREEMENT This Cell Line License Agreement (“Agreement”), effective as of June 20, 2022 (“Effective Date”), is entered and made by and between WuXi Biologic |
|
| December 22, 2023 |
2018 Form of Amended and Restated Indemnification Agreement Exhibit 10.6 INDEMNITY AGREEMENT This Indemnity Agreement, dated as of [•], 2018 is made by and between Aeglea BioTherapeutics, Inc., a Delaware corporation (the “Company”), and [•], a director, officer or key employee of the Company or one of the Company’s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”). RECITALS A. The Co |
|
| December 22, 2023 |
EXHIBIT 99.2 AEGLEA BIOTHERAPEUTICS, INC. 2018 EQUITY INDUCEMENT PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract eligible persons whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company’s future performance thro |
|
| December 22, 2023 |
As filed with the Securities and Exchange Commission on December 22, 2023 As filed with the Securities and Exchange Commission on December 22, 2023 Registration No. |
